Under construction – not a live service
Sign in
Taking people in GreeceNo phase

Follows people with epidermolysis bullosa using Filsuvez gel for skin cancer

Follows people with fragile-skin epidermolysis bullosa treated with Filsuvez gel over years.

Plain-language title generated from the registry record
Registry title: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Key facts

Where
Thessaloniki, GreeceSee the site

Where in Greece

  • Hospital of Skin and Venereal Diseases of ThessalonikiThessaloniki, GreeceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Chiesi Farmaceutici S.p.A.
Trial code
NCT06423573
Record updated
28 September 2026
Original description
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for a minimum of 3 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.Read full original descriptionShow less

A Long-term Non-interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez

In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for a minimum of 3 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.

Inclusion: Patients with a confirmed diagnosis of dystrophic EB or junctional EB.

Exclusion: None.

ClinicalTrials.gov NCT06423573